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Abstract
Introduction: Mitochondrial dysfunction has been suggested as a contributing factor to the pathogenesis of
sepsis-induced multiple organ failure. Also, restoration of mitochondrial function, known as mitochondrial
biogenesis, has been implicated as a key factor for the recovery of organ function in patients with sepsis. Here we
investigated temporal changes in platelet mitochondrial respiratory function in patients with sepsis during the first
week after disease onset.
Methods: Platelets were isolated from blood samples taken from 18 patients with severe sepsis or septic shock
within 48 hours of their admission to the intensive care unit. Subsequent samples were taken on Day 3 to 4 and
Day 6 to 7. Eighteen healthy blood donors served as controls. Platelet mitochondrial function was analyzed by
high-resolution respirometry. Endogenous respiration of viable, intact platelets suspended in their own plasma or
phosphate-buffered saline (PBS) glucose was determined. Further, in order to investigate the role of different
dehydrogenases and respiratory complexes as well as to evaluate maximal respiratory activity of the mitochondria,
platelets were permeabilized and stimulated with complex-specific substrates and inhibitors.
Results: Platelets suspended in their own septic plasma exhibited increased basal non-phosphorylating respiration
(state 4) compared to controls and to platelets suspended in PBS glucose. In parallel, there was a substantial
increase in respiratory capacity of the electron transfer system from Day 1 to 2 to Day 6 to 7 as well as compared
to controls in both intact and permeabilized platelets oxidizing Complex I and/or II-linked substrates. No inhibition
of respiratory complexes was detected in septic patients compared to controls. Non-survivors, at 90 days, had a
more elevated respiratory capacity at Day 6 to 7 as compared to survivors. Cytochrome c increased over the time
interval studied but no change in mitochondrial DNA was detected.
Conclusions: The results indicate the presence of a soluble plasma factor in the initial stage of sepsis inducing
uncoupling of platelet mitochondria without inhibition of the electron transfer system. The mitochondrial
uncoupling was paralleled by a gradual and substantial increase in respiratory capacity. This may reflect a
compensatory response to severe sepsis or septic shock, that was most pronounced in non-survivors, likely
correlating to the severity of the septic insult.
Introduction
Multiple organ failure (MOF) is the leading cause of
death in patients with severe sepsis and septic shock [1].
The cause of MOF is largely unexplained and the patho-
genesis is likely complex. Since the failing organs do not
undergo necrosis or apoptosis to any large extent [2],
there is a possibility of full recovery with supportive
treatment.
Evidence that mitochondrial alterations contribute to
the pathogenesis of MOF has been gathered in animal as
well as human studies (reviewed in [3]) although differ-
ences exist depending on the tissue studied [4]. Restora-
tion of mitochondrial function has also been suggested as
a prerequisite in recovery from MOF. Initial depletion of
mitochondrial DNA (mtDNA) and subsequent activation
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mtDNA copy number were seen in a murine model of
sepsis [5] and recently, increased transcripts of mitochon-
drial biogenetic markers was associated with survival in
patients with severe sepsis and septic shock [6].
M i t o c h o n d r i aa r eu n i q u ei nt h a tt h e yc o n t a i nt h e i r
own genome that is maternally inherited. Compared to
nuclear DNA, mtDNA is more prone to damage because
the DNA is not bound to histones and has reduced
capacity of DNA repair [7]. A fall in mtDNA in mono-
nuclear cells was recently shown in patients with sepsis
[8] and a temporal increase of mtDNA in blood cells
from septic patients has been associated with improved
outcome [9].
Platelets are anucleated cells that contain two to eight
mitochondria per cell [10] with their main function in
the process of coagulation. Recently, they have been
shown to play a role in innate immunity, containing
toll-like receptors and interplaying with other immune
cells [11]. Further, platelet mitochondria have been pro-
posed to serve as a marker for changes in mitochondrial
function occurring in senescence and age-related
diseases [12-14].
Although mitochondrial biogenesis seems to be trig-
gered early on in sepsis the temporal evolution or func-
tional outcome has not been avidly studied. This is in
part due to the ethical and practical problems of obtain-
ing adequate mitochondrial samples from vital organs in
critically ill patients. In order to address this question
we examined changes in platelet mitochondrial respira-
tory function during the first week in patients with
severe sepsis or septic shock and evaluated how these
changes correlated with clinical parameters, severity
scores and mortality. Using high-resolution respirometry
we analyzed integrated mitochondrial function in both
intact platelets with preserved intra- and extracellular
environment as well as the contribution of individual
respiratory complexes in permeabilized cells. By evaluat-
ing platelet mitochondrial function in the presence or
absence of the patients’ o w np l a s m aw ea d d r e s s e dt h e
possible influence of soluble factors affecting respiratory
capacity.
Preliminary data of this study have been presented
at the annual International Sepsis Forum meeting
2010 [15].
Materials and methods
Study population
This study was approved by the scientific ethical com-
mittee of Copenhagen County, Denmark (H-C-2008-
023) and the regional ethical review board of Lund,
Sweden (113/2008). Patients were recruited from the
intensive care units (ICU) of Lund University Hospital
and Copenhagen University Hospital, Rigshospitalet.
Written, informed consent was obtained from the
patient or next of kin. In Denmark, consent from the
patient’s primary health care physician was also required
if the patient was unconscious. Eighteen patients with
severe sepsis or septic shock, as previously defined [16],
were included within 48 h after their admission to the
ICU. Diagnosis of sepsis should have been made no
more than 24 h prior to ICU admission. Patients with
platelet count <10 × 10
9/L, pregnancy, known mito-
chondrial disease or hematological malignancy were
excluded. Blood samples were taken at three different
time points during the first week following admission to
the ICU; within the first 48 h (Day 1 to 2), on Day 3 to
4 and Day 6 to 7. If a patient received platelet transfu-
sion a minimum of six hours had to pass before blood
sampling. Eighteen healthy blood donors served as con-
trols following written, informed consent.
Chemicals and sample preparation
All chemicals were purchased from Sigma-Aldrich (St
Louis, MO, USA) if not stated otherwise. In patients, a
maximal volume of 40 mL of blood was drawn from an
existing arterial line in K2EDTA tubes (Vacuette®, Grei-
ner Bio-One GmbH, Kremmünster, Austria). In con-
trols, blood samples were taken at the time of planned
donation via venous puncture in K2EDTA tubes. Plate-
lets were freshly prepared by centrifugation 10 to 15
minutes at 300 × g resulting in a platelet-rich plasma
(PRP). This PRP was collected and centrifuged for five
minutes at 4,600 × g producing a close to cell-free
plasma and a platelet pellet. The pellet was resuspended
in 1 to 3 mL of plasma by gentle pipeting to obtain a
highly enriched PRP.
High-resolution respirometry
Measurement of mitochondrial respiration was per-
formed in a high-resolution oxygraph (Oxygraph-2k
Oroboros Instruments, Innsbruck, Austria [17]) at a
constant temperature of 37°C. Platelets were suspended
in the 2 mL glass chamber at a concentration of 50 to
200 × 10
6/mL. Calibration with air-saturated Millipore
water was performed daily. For experiments in intact
cells, platelets were suspended in either phosphate buf-
fered saline (PBS) with addition of 5 mM glucose or in
their own plasma. For respiration measurements in per-
meabilized cells, platelets were suspended in a mito-
chondrial respiration medium (MiR05) containing
sucrose 110 mM, HEPES 20 mM, taurine 20 mM, K-lac-
tobionate 60 mM, MgCl2 3m M ,K H 2PO4 10 mM,
EGTA 0.5 mM, BSA 1 g/l, pH 7.1 [17]. Oxygen solubi-
lity factors relative to pure water were set to 0.92 for
MiR05 and PBS glucose and 0.89 for plasma. Data were
collected using software displaying real-time oxygen
concentration and oxygen flux, that is, the negative time
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Oroboros Instruments, Innsbruck, Austria).
Experimental protocol for intact cells
Respiration was first allowed to stabilize without any addi-
tions at a routine state, that is, in the physiological cou-
pling state controlled by cellular energy demands
on oxidative phosphorylation (OXPHOS). Then the
ATP synthase inhibitor oligomycin was added to reveal
respiration independent of ADP phosphorylation (oligo-
mycin-induced state 4, henceforth denoted as state 4). To
evaluate maximal capacity of the electron transfer system
(ETS) the protonophore, carbonyl cyanide p-(trifluoro-
methoxy) phenylhydrazone (FCCP) was titrated until no
further increase in respiration was detected. The ETS was
then inhibited by adding rotenone (Complex I inhibitor)
and antimycin-A (Complex III inhibitor). The remaining,
primarily non-mitochondrial oxygen consumption (resi-
dual) was subtracted from the different respiratory states
in further analyses. In intact cells, to determine the relative
contribution of the different respiratory states, a control
ratio was calculated as the ratio of maximal FCCP-stimu-
lated respiration and state 4 respiration.
Experimental protocol for permeabilized cells
The next protocol was established to separate the
respiratory capacities through Complex I and Complex
II as achieved in conventional respirometric protocols.
In addition, maximal phosphorylating and non-phos-
phorylating respiration were measured as stimulated by
combined succinate plus NADH-related substrate sup-
ply. This substrate combination is required as a basis to
reconstitute the citric acid cycle function in permeabi-
lized cells or isolated mitochondria, with convergent
Complex I and II electron input [18]. Sequential addi-
tions were performed in a substrate, uncoupler, inhibitor
titration (SUIT) protocol. Platelets were allowed to sta-
bilize at routine respiration without exogenous sub-
strates in MiR05, and were then permeabilized with
digitonin in order to access the mitochondria with the
different respiratory substrates and ADP. In a different
set of experiments the optimal concentration of digito-
nin was set to 1 μg/1 × 10
6 platelets (data not shown).
Respiration through Complex I, driven by NADH-
related substrates, was evaluated by adding first malate
(5 mM) and pyruvate (5 mM), then ADP (1 mM), and
finally glutamate (5 mM) (CIOXPHOS, or state 3CI). Maxi-
mal OXPHOS capacity by convergent input through
both Complex I and Complex II was obtained by
sequentially adding 10 mM succinate (CI+IIOXPHOS,o r
state 3CI+II) after NADH-related substrates and ADP.
State 4 (with CI and CII substrates present) was evalu-
ated by adding oligomycin and maximal capacity of the
ETS was obtained by titrating FCCP (CI+IIETS). Inhibi-
tion of Complex I by rotenone revealed the ETS capa-
city supported by succinate through Complex II alone
(CIIETS). Finally, residual oxygen consumption was
determined by addition of antimycin-A. In permeabi-
lized cells, control ratios were calculated for both maxi-
mal capacity of OXPHOS and ETS by dividing the
respective rate with state 4 respiration. After experi-
ments, analyzed samples were stored at -80 °C.
Determination of platelet mtDNA content
The analysis of platelet mtDNA content was adapted
from [19] with modifications. Frozen samples were
thawed and diluted 500 times in a lysis buffer (10 mM
TRIS-HCl, 1 mM EDTA, salmon sperm DNA 1 ng/μl,
pH 8.0). 10 μl of this dilution was amplified in a 25 μl
PCR reaction containing 1 × Power SYBR® Green PCR
Master Mix using an ABI Prism 7000 real-time PCR
machine (Applied Biosystems Inc., Foster City, CA,
USA) and 100 nM of each primer (Eurofins MWG-
operon, GmbH, Ebersberg, Germany). The primers tar-
geted the human mitochondrial COX-1 gene (forward:
CCC CTG CCA TAA CCC AAT ACC A, reverse: CCA
GCA GCT AGG ACT GGG AGA GA). The threshold
cycle (Ct) values were related to a standard curve using
cloned PCR products (kindly provided by P. Schjerling
University of Copenhagen, Denmark). Due to relatively
high variation, samples were analyzed in pentaplicate.
Cytochrome c determination
Human cytochrome c (Cyt c) content was quantified
using an immunoassay kit (DCTC0, Quantikine®, R&D
systems, Abingdon, UK). Frozen samples where thawed
and sonicated and subsequently processed according to
the manufacturer’s instructions.
Data analysis
All absolute values are presented as mean ± SEM or
individual values. Ratios are presented as median with
range. Graph Pad PRISM (GraphPad Software version
5.01, La Jolla, CA, USA) was used for statistical evalua-
tion. Analysis between two groups was performed using
unpaired or paired Student’s t-test as appropriate. For
comparison of three or more groups one-way ANOVA
or repeated measurements ANOVA were used as appro-
priate. Kruskal-Wallis or Friedmans non-parametric
tests were used for comparisons of ratios and Mann-
Whitney U test for mortality data. For missing values in
repeated measurements (in total two values in separate
patients) “last value carried forward” was employed. One
negative value in state 4 respiration was omitted in the
analysis presented in Figure 1B. A P-value less than 0.05
was considered significant.
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Study population
A total of 18 patients with severe sepsis or septic shock
were studied and 18 healthy blood donors served as
controls. Table 1 shows demographics, source of sepsis,
severity of illness and outcome of the septic patients
and demographics for the healthy controls. Table 2
shows clinical characteristics of the septic patients dur-
ing the first week at the ICU. A total of four patients
received platelet transfusion; two at the day of sample
one and two at the day of sample three. No medication
with known platelet interaction was administered during
the study.
Mitochondrial respiration of intact platelets
In intact platelets, FCCP-titrated maximal respiration
gradually increased in septic patients during the first
week after admission to the ICU. The maximal respira-
tion (pmol O2 xs
-1 ×1 0
-8 platelets) increased signifi-
cantly from Day 1 to 2 to Day 6 to 7, 29% in plasma (20.6
± 1.2 vs 26.7 ± 2.1) and 45% in PBS glucose (18.9 ± 1.4 vs
27.4 ± 2.2). Compared to controls the increase was 60%
in plasma (16.7 ± 0.8 vs 26.7 ± 2.1) and 85% in PBS glu-
c o s e( 1 5±0 . 8v s2 7 . 4±2 . 2 )a tD a y6t o7( F i g u r e1 A ) .
State 4 respiration in PBS glucose was not different from
controls and did not change significantly over the week.
In contrast, state 4 respiration determined in the patients’
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Figure 1 Mitochondrial respiration of intact platelets suspended in their own plasma or PBS glucose. A. Maximal respiration induced by
titration of the protonophore FCCP demonstrated a significant increase in both media, from Day 1 to 2 to Day 6 to 7 as well as compared to
controls. B. State 4 respiration in presence of the ATP synthase inhibitor oligomycin was significantly higher on Day 3 to 4 and Day 6 to 7 in
platelets suspended in plasma compared to controls, whereas no difference was seen in PBS glucose. C. The control ratio (maximal respiration/
state 4 respiration) in platelets incubated in patients’ own plasma was significantly lower at Day 3 to 4 compared to controls. Mean values ±
SEM (A, B) and median with interquartile range and range (C), n = 17 to 18, *P < 0.05.
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controls at Day 3 to 4 and Day 6 to 7 and also signifi-
cantly higher compared to PBS glucose at Day 1 to 2 and
Day 3 to 4 but not at Day 6 to 7 (Figure 1B). When
adjusted for Cyt c content, state 4 respiration in plasma
was significantly higher, compared to control, also at Day
1 to 2 (data not shown). The control ratio (FCCP-titrated
maximal respiration/state 4 respiration) of mitochondria
in septic plasma decreased over the first days, due to the
increase in state 4 respiration, and was significantly lower
than controls at Day 3 to 4 (Figure 1C).
Mitochondrial respiration of permeabilized platelets
A representative trace of the SUIT protocol used in per-
meabilized platelets is depicted in Figure 2A. In the pre-
sence of saturating Complex I substrates respiration,
CIOXPHOS, increased by 47% from Day 1 to 2 to Day 6
t o7a n dw a s4 3 %h i g h e rD a y6t o7c o m p a r e dt oc o n -
trols (22.7 ± 1.8, 33.3 ± 2.4 and 23.4 ± 1.2, respectively)
(Figure 2B). No differences in the relative contribution
of the different Complex I-linked respiratory substrates
(pyruvate, malate, glutamate) were detected between
controls and septic patients (data not shown). CIIETS
increased by 39% from Day 1 to 2 to Day 6 to 7 and
was 67% higher Day 6 to 7 compared to controls (14.6
± 1.0, 20.2 ± 1.1 and 12.1 ± 0.7, respectively). CI + IIETS
increased by 54% from Day 1 to 2 to Day 6 to 7 and
was 60% higher Day 6 to 7 compared to controls (37.3
± 2.4, 57.5 ± 4.3 and 36.0 ± 1.7, respectively). State 4
respiration also increased gradually to some extent in
septic patients and was significantly higher compared to
controls at Day 6 to 7 with a difference of 29% (4.9 ±
0.2 vs. 6.3 ± 0.4) (Figure 2B). Control ratios for ETS (CI
+I I ETS /state 4) and OXPHOS (CI + IIOXPHOS /state 4)
both increased significantly during the first week of sep-
sis due to the more pronounced increase in maximal
respiratory capacity compared to the increase in state 4
respiration (Figure 2C). No significant changes in
respiration rates of permeabilized platelets were detected
at Day 1 to 2 compared to controls.
Respiratory changes in platelet mitochondria in relation
to clinical parameters and mortality
Patients were divided into survivors and non-survivors
according to 90-day mortality that was 33% (6/18). At
Day 6 to7 both FCCP-induced maximal respiration (CI
+I I ETS)a sw e l la st h ec o r r e s p o n d i n gc o n t r o lr a t i ow a s
significantly higher in non-survivors compared to survi-
vors (Figure 3). A significant difference in non-survivors
compared to survivors was also seen in CIOXPHOS as
well as the control ratio (CI + IIOXPHOS/state 4) with a
similar trend in CI + IIOXPHOS and CIIETS respiration
states (data not shown). We did not find any correlation
between mitochondrial respiration and severity of illness
as measured by APACHE II, SAPS- and SOFA score
and noradrenaline requirement at any of the measured
time points (data not shown).
Quantification of platelet mtDNA and Cyt c content
In order to determine changes of mitochondrial number
and protein content in analyzed platelets, we measured
Table 2 Clinical characteristics of patients at the time of blood sampling
Day of sample 1 Day of sample 2 Day of sample 3
SOFA (median (IQR)) 10 (7 to 13) 9 (5 to 11) 7 (3 to 9)
Noradrenaline infusion rate (μg/kg/min) 0.19 ± 0.04 0.09 ± 0.04 0.01 ± 0.01
Maximum lactate (mmol/L) 3.5 ± 0.6 2.0 ± 0.3 1.3 ± 0.3
Average B-glucose level (mmol/L) 9.5 ± 0.4 8.6 ± 0.6 8.0 ± 0.4
Platelet count (x 10
9/L) 153 ± 24 146 ± 23 146 ± 22
CRP (mg/L) 203 ± 21 131 ± 24 57 ± 16
PCT (ng/mL) 73 ± 51 30 ± 21 4 ± 2
Platelet transfusion (patients) 2 0 2
Dialysis (patients) 3 3 3
CRP, C-reactive protein; IQR, interquartile range; PCT, procalcitonin; SOFA, sequential organ failure assessment.
Table 1 Demographic and clinical characteristics of
patients and controls
Patients (n = 18) Controls (n = 18)
Age 64 (50 to 73) 51 (38 to 60)
Male/Female 14/4 12/6
Source of sepsis:
- Chest 8
- Abdominal 7
- Soft tissue 3
SAPS II 46 (41 to 51)
APACHE II 24 (16 to 26)
Severe sepsis/septic shock 3/15
90-day outcome dead/alive 6/12
Data presented as median with interquartile range (IQR) or number of
patients. SAPS, simplified acute physiology score; APACHE, acute physiology
and chronic health evaluation score.
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Page 5 of 11two different parameters, mtDNA and Cyt c.T h e
amount of mtDNA did not differ in platelets of septic
patients compared to controls and did not change dur-
ing the course of sepsis (Figure 4A). In contrast, we
found a significant increase in mitochondrial Cyt c
content in platelets of septic patients from Day 1 to 2 to
Day 6 to 7 but not compared to controls (Figure 4B).
Respiration parameters adjusted to mtDNA content still
showed a significant increase over the week in septic
patients (example given in Figure 4C). In both intact as
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Figure 2 Mitochondrial respiration of permeabilized platelets. A. Representative trace of oxygen consumption rate using a substrate,
uncoupler, inhibitor titration protocol. Respiratory complexes activated and the induced respiratory states are defined below the x-axis. Platelets
were permeabilized with digitonin with simultaneous addition of malate and pyruvate (DMP). Oxidative phosphorylation (OXPHOS) was
stimulated by subsequent addition of ADP followed by an additional Complex I (CI) substrate glutamate (Glu). Addition of the Complex II (CII)-
linked substrate succinate (Succ) enabled convergent electron input via both complex I and complex II. OXPHOS was inhibited by oligomycin
(Oligo) revealing state 4 respiration. Maximal respiratory capacity of the electron transfer system (ETS) was induced by titration of FCCP. Inhibition
of Complex I by rotenone (Rot) revealed Complex II-supported respiration. The Complex III inhibitor antimycin-A (Anti) left residual, primarily
non-mitochondrial oxygen consumption. B. Temporal changes of different respiratory states during the first week of sepsis in patients compared
to controls. Complex I-dependent respiration during oxidative phosphorylation (CIOXPHOS), FCCP-titrated maximal respiration with complex II
(CIIETS), and convergent substrate input (CI + IIETS) all increased significantly in patients during the first week of sepsis both compared to Day 1
to 2 and to controls. State 4 was only increased at Day 6 to 7 compared to controls. Of note, there was no significant difference in respiratory
capacity of any respiratory state in patients at the earliest time point analyzed, Day 1 to 2 of admission, compared to controls. C. The control
ratio (CI + IIETS/state 4) increased significantly during the first week of sepsis both compared to Day 1 to 2 as well as to controls. Mean values ±
SEM (B) and median ± range (C), n = 16 to 18, *P < 0.05 compared to Day 1 to 2, § P < 0.05 compared to controls.
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adjusted to Cyt c did not change significantly over the
studied time period (example given in Figure 4D).
Discussion
In this study we demonstrate several alterations in plate-
let mitochondrial respiratory function during the course
of the first week in patients admitted to the ICU due to
severe sepsis or septic shock. First, plasma from septic
patients induced an elevated state 4 respiration (uncou-
pling) resulting in a decreased control ratio (FCCP-
titrated maximal respiration/state 4 respiration) which
was not seen when plasma was removed and platelets
were incubated in “clear” respiration media such as PBS
or the mitochondrial respiration medium MiR05. Sec-
ond, mitochondrial respiratory capacity increased gradu-
ally and extensively during the week which was
paralleled by an increase in mitochondrial Cyt c content.
Third, non-survivors had a significantly more elevated
level of respiratory capacity at Day 6 to 7 compared to
survivors.
Platelets incubated in their own septic plasma had a
significantly elevated state 4 respiration at Day 3 to 4
and Day 6 to 7 compared to controls resulting in a
decreased control ratio. Increased state 4 respiration and
reduced control ratios have been demonstrated pre-
viously in sepsis. D’Avila et al.f o u n dm i t o c h o n d r i a l
uncoupling in brain homogenates in a 24 h cecal liga-
tion and puncture model (CLP) model in mice [20].
Also, plasma taken from septic patients at Day 1 and
Day 7 induced increased state 4 respiration in peripheral
blood mononuclear cells from healthy controls [21].
State 4 respiration, that is, when oxidation of respiratory
substrates is not coupled to ATP synthesis, is the result
of “leak” of protons, slip of protons within the proton
pumps and exchange of cations across the inner mito-
chondrial membrane. The formation of reactive oxygen
species (ROS) could also contribute to some extent to
oxygen consumption and in the case of whole and per-
meabilized cell analysis, also non-mitochondrial oxida-
tive processes. However, both of these latter processes
were removed from the respiratory rates in the present
study by subtracting the low residual oxygen consump-
tion following Complex III inhibition. The mitochon-
drial permeability transition (mPT) has been implicated
in sepsis [22,23] but cannot readily explain the elevated
state 4 respiration in the present data. Activation of
mPT leads to loss of mitochondrial matrix substrates as
well as dissipation of the proton-motive force which
uncouples as well as inhibits respiration [24], but no
inhibition of the ETS was detected in the present inves-
tigation. Uncoupling proteins (UCPs) have been impli-
cated in sepsis where UCP3 has been shown to be
upregulated in muscle in a CLP model in rats and
UCP2 deficient mice were protected from LPS-induced
liver failure [25,26]. Also, ROS production is increased
in sepsis and a proton leak; ROS feedback loop has been
suggested where ROS increase proton leak which in
turn reduces ROS production via lowering of the pro-
ton-motive force [27,28]. In the present study, no
increase in state 4 respiration was found when plasma
was removed and platelets were incubated in PBS glu-
cose. This suggests presence of a soluble or a rapidly
metabolized factor in septic plasma that can induce
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of endogenous pathways such as uncoupling proteins.
Whatever the cause of the uncoupling it remains to be
elucidated if this stands for a true pathophysiological
mechanism or constitutes a protective mechanism in
regulating ROS production.
Concomitantly, we found that the respiratory capacity of
the platelet mitochondria increased by 29 to 54% depend-
ing on experimental conditions and up to about 85% com-
pared to controls. The temporal increase was seen both at
the level of individual complexes as well as in integrated
respiration of intact platelets and was significant already
early in the disease process (Day 3 to 4). mtDNA copy
number per platelet remained stable over the seven days
investigated suggesting that the increase did not come
from an increased number of organelles in the cell and is
in accordance with a previous study [9]. In contrast, we
noted a 19% rise in Cyt c protein, used here as a marker of
cellular content of mitochondrial proteins. The body
copes with increasing demands of energy supply via mito-
chondrial biogenesis [29]. Cytokines which are known to
be elevated in sepsis have also been shown to activate reg-
ulators of mitochondrial biogenesis such as peroxisome
profilerator-activated receptor g coactivator -1a (PGC-1a)
[30]. Biogenesis has also been proposed to play an impor-
tant part in the recovery following sepsis. In a murine
model of Staphylococcus aureus sepsis, Haden et al.
demonstrated an early fall (Day 1) in liver mtDNA copy
number. Subsequently they noted an increase in transcrip-
tion of nuclear respiratory factor (NFR)-1, NRF-2,
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Figure 4 Quantification of mitochondrial DNA (mtDNA) and cytochrome c (Cyt c) content in platelets. A. Platelet mtDNA content did not
change in the septic patients during the first week or compared to controls. B. Cyt c content increased significantly from Day 1 to 2 to Day 6 to
7 in septic patients but not compared to controls. C. Maximal FCCP-titrated respiration (CI + IIETS) adjusted to mtDNA increased similarly as when
adjusted to platelet count. D. Maximal respiration (CI + IIETS) adjusted to Cyt c demonstrated an increasing trend but no significant change.
Mean values ± SEM, n = 16-18, *P < 0.05 compared to Day 1 to 2, § P < 0.05 compared to controls.
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already at Day 2 after the induction of sepsis. At Day 3
mtDNA copy numbers were restored to normal values [5].
Apart from increased number of organelles, biogenesis
can also lead to increased density of respiratory complexes
per organelle [31,32] and reversible protein phosphoryla-
tion has been suggested to be a key mechanism in modu-
lating the post-translational function of respiratory
complexes [33]. Some of the observed increase in respira-
tory capacity could be related to a high turnover of plate-
lets in sepsis creating a more freshly produced pool of
mitochondria being studied. The difference in respiratory
capacity, if any, of newly produced platelets compared to
the circulating pool is not known. However, we find it
unlikely that such a difference may explain the pro-
nounced increase in respiration rate, as much as 85%,
found in the septic patients. Also, there was no correlation
between platelet count or change in platelet count and
respiratory capacity at any of the time points studied. Four
patients received platelet transfusions on the day of sam-
pling which could confound the results. However, exclud-
ing the patients’ data completely or from specific days of
transfusion did not influence the main findings or conclu-
sions of the study (data not shown). The results from the
present study support the hypothesis that in the recovery
from sepsis with organ failure there is increasing metabolic
demands that is met via a progressive rise in mitochon-
drial respiratory capacity. The temporal increase in Cyt c
suggests that this process is mediated, at least in part, via a
higher mitochondrial density of ETS-related proteins. At
present the correlation between a given increase in ETS
proteins and the resulting change in respiratory capacity is
unknown.
Surprisingly, non-survivors at 90 days displayed signifi-
cantly elevated levels of respiratory capacity compared to
survivors at Day 6 to 7; both in absolute values as well as
expressed as control ratios. This stands somewhat in con-
trast with recent findings that survival after severe sepsis
was associated with early activation of mitochondrial bio-
genesis [6]. Also, survivors from septic or cardiogenic
s h o c ks h o w e da ni n c r e a s ei nm t D N A / n D N Ar a t i oi n
blood cells compared to non-survivors [9] although this
finding could have been caused by a variation of different
leucocyte proportions [8]. Tissue differences set aside,
the findings of the present study represent the functional
result of the various stimuli on mitochondria during the
septic process in contrast to experiments using different
markers of mitochondrial biogenesis where the relation-
ship to functional outcome is hard to predict. We pro-
pose that a more severe septic insult or a more marked
host response to the bacterial invasion leads to higher
levels of cytokines and stimulants of mitochondrial bio-
g e n e s i sr e s u l t i n gi nam o r ee l e vated respiratory capacity
in non-survivors. Lending support to this is the recent
study by Kellum et al. showing that 90-day mortality was
higher in patients with severe sepsis that had the highest
cytokine response when presenting at the emergency
department [34].
In contrast to several other studies [35-37] we were
unable to detect any functional inhibition of the respira-
tory complexes in the septic patients. These differences
could be related to animal vs. human subjects, tissue speci-
ficity or different experimental conditions. In a high turn-
over cell type such as platelets it is also possible that an
early initiation of the stimulatory process to increase
respiration seen in the present study obscures an eventual
early negative influence on mitochondrial respiration.
The limitations of the present study include the rela-
tively small group sizes. Further, the generalizability of
the present findings to other vital organ systems is at
present not known.
Conclusions
To our knowledge this is the first study of temporal
changes in mitochondrial respiratory function in intact,
viable and permeabilized platelets of septic patients. Pla-
t e l e t sa r ea ne a s ya c c e s s i b l es o u r c eo fv i a b l em i t o c h o n -
dria and proved to be well suited for repeated sampling
and analysis of respiration. The present data indicate the
presence of a soluble plasma factor in the initial stage of
sepsis inducing uncoupling of platelet mitochondria
leading to a decreased control ratio but no inhibition of
respiratory complexes. The mitochondrial uncoupling
was paralleled by a gradual and pronounced increase in
mitochondrial respiratory capacity. This probably
reflects a compensatory mitochondrial biogenic response
to severe sepsis or septic shock, that was most pro-
nounced in non-survivors, likely correlating to the sever-
ity of the septic insult.
Key messages
￿ In the early phase of sepsis, intact platelets sus-
pended in their own plasma (but not in other
media) demonstrated an elevated basal non-pho-
phorylating respiration (state 4) indicating a respira-
tory uncoupling mediated by a soluble factor in
plasma.
￿ Multiple parameters of platelet mitochondrial
respiratory capacity gradually and substantially
increased during the first week of sepsis.
￿ N o n - s u r v i v o r sa t9 0d a y sd e m o n s t r a t e dm o r ee l e -
vated respiratory capacities compared to survivors.
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